PFE vs CVS
Pfizer · CVS Health
| PFE Pfizer Healthcare | CVS CVS Health Healthcare | |
|---|---|---|
| Market | ||
| Price | $30.52 +1.90% | $90.25 -0.09% |
| Market cap | $174.0B | $115.4B |
| P/E (TTM) | 40.1 | 23.6 |
| Dividend yield | 5.38% | 3.49% |
| 52-week range | $23.62 – $30.67 | $69.51 – $110.68 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 | CVS Health's Aetna MBR Just Hit 84.6% — Five Straight Beats Say The Turnaround Is Real (C… Jun 30, 2026 |
| Latest earnings | ||
| Reported | — | Aug 5, 2026 |
| Revenue | — | $106.1 billion +7.3% YoY |
| EPS | — | $2.31 |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +7.3% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Shared topics: GLP-1
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.